Reaction
Budd-Chiari Syndrome reporting signals
As of the last recalculation, Budd-Chiari Syndrome appears in 253 FAERS reports alongside 2 co-occurring drug terms. The strongest observed disproportionality signal is ECULIZUMAB (PRR 89.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Eculizumab | 48 | 89.5 | 89.5 |
| Ravulizumab | 4 | 24.7 | 24.7 |